Hannah Slater

The FDA granted breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.

Marking the first US applications for pembrolizumab in breast cancer, the applications are based on data from the KEYNOTE-355 and KEYNOTE-522 trials, respectively.

In addition to being approved to detect the HER2 biomarker in breast cancer, the assay was approved as a companion diagnostic for trastuzumab therapy.

These findings have serious implications for future cancer care and underscore the need to resume cancer care and screening.

The FDA granted breakthrough therapy designation to MK-6482 for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma and orphan drug designation to MK-6482 for von Hippel-Lindau disease.

Updated findings further evaluate the effectiveness of various treatments of COVID-19 for patients with cancer and reveal possible racial disparities in enrollment of clinical trials.

The study is evaluating poziotinib in patients who were previously treated for non-small cell lung cancer with HER2 exon 20 insertion mutations.

Within this study, satisfaction was markedly higher in those treated with apixaban, and adherence rates appeared to be similar between both modalities in women undergoing surgery for gynecologic cancer.

This research suggested the need for reassessment of the methods by which childhood cancer treatment delivery are approached during crises.

Though a significant shift in coverage frameworks was detected in this study, future research should continue to monitor coverage and its possible impact on test utilization.

In this study, investigators found that the hydrogel spacer has a favorable risk-benefit profile for patients receiving radiotherapy for prostate cancer.

This data may help to inform future recommendations for surveillance of BRCA1/2-associated cancers, according to researchers.

The agent is now the first and only approved CAR T-cell therapy to treat adult patients with relapsed or refractory mantle cell lymphoma.

Though the video did not have a statistically significant impact, those assigned to watch the video appeared to be more informed about hospice care and reported more favorable perceptions of hospice.

The expert from the Fox Chase Cancer Center discussed a paper recently published regarding alternative multidisciplinary management options for patients with NSCLC during the COVID-19 pandemic.

A study of individuals in Ohio who were uninsured or had Medicaid insurance at the time of their cancer diagnosis suggested that Medicaid expansion is correlated with a narrowing of a critical cancer outcome disparity.

These findings suggested that instituting annual breast cancer screening with MRI earlier may reduce breast cancer mortality by at least 50% in survivors of childhood cancer.

The study is evaluating ruxolitinib in patients with refractory or steroid-dependent chronic graft-versus-host disease compared to best available therapy.

These results indicated the necessity for providers to address the concerns of AYAs with cancer, including those of a spiritual nature.

Both patients and clinicians agreed that preferences related to quality-of-life should be considered in treatment decision making, though barriers still remain.

These results suggest the need for future studies to examine scalable interventions to improve fatigue in women with gynecologic cancers.

The findings indicated that a fasting mimicking diet is safe and effective as an adjunct to chemotherapy in women with early breast cancer.

This long-term record of patients with cancer found that almost half of those who were newly diagnosed proceeded to fertility preservation and returned for follow-up within 21 months of cancer treatment.

The National Comprehensive Cancer Network published a document intended for patients to understand how CAR-T cells work and what side effects are associated with the treatment.

The board-certified gastroenterologist discussed the lack of screenings being conducted due to the COVID-19 pandemic, and how many physicians have tried to circumvent this issue.

The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.

This study found that smoking was associated with an increased risk of gastric cancer incidence and mortality, while not drinking was correlated with a stronger beneficial effect of garlic supplementation on gastric cancer prevention.

In this multi-institutional study, regorafenib demonstrated modest clinical efficacy in heavily pretreated patients with biliary tract cancer.

This study demonstrated a possible advantage in overall survival for patients taking NSAIDs during chemoradiation for head and neck squamous cell carcinoma.

The tool was shown to be a reliable and accurate tool for measuring patient-reported financial toxicity in patients with head and neck cancer.